CARLSBAD, Calif. - Ionis Pharmaceuticals Inc. (NASDAQ:IONS) announced the appointment of Ludwig Hantson to its board of directors, effective immediately, according to a press release statement. The appointment comes as the company’s stock has surged 111% over the past year, trading at $74.48 with a market capitalization of $12.31 billion.
Hantson brings over 30 years of experience in biopharmaceutical and medical device companies. He served as chief executive officer and board member of Alexion from 2017 to 2021, prior to its acquisition by AstraZeneca.
Before Alexion, Hantson served as president of Baxter Bioscience, where he led the spin-off of Baxalta and served as its chief executive officer and board member. He previously held senior leadership roles at Novartis across North America and Europe, including chief executive officer of North America, and spent 13 years at Johnson & Johnson in various positions.
Hantson holds a master’s degree in physical education and a doctorate in motor rehabilitation and physical therapy from the University of Louvain in Belgium.
"We are pleased to welcome Dr. Hantson to the board," said Joseph Loscalzo, chairman of the Ionis Board of Directors. "Ludwig’s biopharma executive leadership experience will be especially meaningful as Ionis prepares for a steady cadence of new commercial launches, including two additional independent launches this year." The company reported 47.53% revenue growth in the last twelve months, and according to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value. For deeper insights, investors can access a comprehensive Pro Research Report on IONS, one of 1,400+ US equities covered.
The company also recently announced the appointment of Peter Reikes to the board and the retirement of two long-serving directors, Joseph Wender and Lynne Parshall.
Ionis Pharmaceuticals develops RNA-targeted medicines and has marketed medicines and a pipeline in neurology, cardiometabolic disease and other therapeutic areas.
In other recent news, Ionis Pharmaceuticals has made significant strides with its first-quarter 2026 results, prompting Oppenheimer to raise its price target to $110 while maintaining an Outperform rating. The company has increased its full-year 2026 total revenue guidance to between $875 million and $900 million, up from the previous range of $800 million to $825 million. Additionally, Ionis announced that Biogen will advance the Alzheimer’s drug diranersen to registrational development following promising results from the Phase 2 CELIA study. In the hepatitis B treatment space, H.C. Wainwright reiterated a Buy rating with a $125 price target for Ionis, following positive Phase 3 data from partner GlaxoSmithKline’s studies. These studies reported a 19% functional cure rate in the overall chronic hepatitis B population. Meanwhile, Stifel raised its price target on Ionis to $86, maintaining a Hold rating, as the company navigates pricing adjustments for Tryngolza in anticipation of approval for a broader sHTG patient population. Wolfe Research also reiterated an Outperform rating, with a $98 price target, noting Ionis’s significant 85% reduction in acute pancreatitis and the upcoming data from a rival’s plozasiran SHTG study. These developments mark a period of strategic growth and adaptation for Ionis Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for IONS plus thousands of other stocks and find your next hidden gem with massive upside.